News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
genesis biomed
Algorithms and Image Biomarkers. Radiomics as another piece of precision oncology
Personalized medicine
Radiomics is revolutionising medical image interpretation
Partners - GENESIS Biomed
lim global
LIM Global, Digital transformation and rebranding by eMascaró
The objectives were clear: communicate the brand's values, encourage customer attraction, entice…
Partners - LIM Global
owl
OWL Metabolomics and Sagimet Biosciences closed an agreement to use OWL´s services in Sagimet´s Phase 2b FASCINATE-2 Clinical Trial
Healthcare
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with…
Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada CVRx, Inc.
Ysios Capital closes its third fund at €216 million ($260 million)
Ysios BioFund 3 (YBF 3) is the firm’s largest fund to date. To invest in up to 15 companies in…
Partners - Ysios Capital Partners
foto talento
Pandemic consolidates the trend of job and talent growth in the biotech sector
BioSpain
Biotech companies are expanding their workforce amid the pandemic, accentuating in 2020 the growth…
foto noticia asabys
Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations
Financing
Asabys, who has been in business for almost 3 years, has considered sustainability as a fundamental…
Partners - Asabys Partners
oryzon
ORYZON to present new clinical data and corporate updates at international conferences in May and June
Healthcare
The conferences are: BioEquity Europe Digital, Foro Medcap BME 2021, Oxford Global’s Online Drug…
Partners - Oryzon Genomics
edificio oryzon
ORYZON reports results and corporate update for quarter ended March 31, 2021
Healthcare
La compañía invierte 3,6 M€ en I+D sin impactos significativos derivados de la pandemia covid-19
Partners - Oryzon Genomics
3P Facilities
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours
Healthcare · Innovative drugs · Advanced therapies · BioSpain
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement…
Partners - 3PBIOVIAN